Yahoo Finance

Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and ...
Yahoo Finance

Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU

BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of ...
Nasdaq

Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)

BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has initiated the Phase 1 trial for HMI-203, a one-time, ...
The Business Journals

Big Pharma-backed startup to go public by merging with gutted Homology

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A three-year-old biotech backed ...
GEN

One in a Million: Homology Medicines Targets New Approach for Rare Genetic Diseases

The field of human genetics is discovering disease-causing mutations at a rapid pace. These mutations drive thousands of rare, debilitating and fatal disorders. While some treatments are available to ...
Nasdaq

Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model

BEDFORD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today a new approach to its AAVHSC platform that ...